missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human CD79 alpha ELISA Kit
Description
Human CD79 alpha quantitates human CD79 alpha in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human CD79 alpha.
CD79a is a disulphide-linked heterodimer that includes B29 (CD79b) polypeptide. CD79a is a B lymphocyte antigen receptor with an antigen-specific surface component Ig (immunoglobulin) that associates with Ig-alpha and Ig-beta, necessary elements for the expression and function of the B-cell antigen receptor. CD79a first appears at pre-B cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Diseases associated with CD79a include Agammaglobulinemia 3 and Agammaglobulinemia, Non-Bruton type.
Specifications
Specifications
| Accession Number | B-cell antigen receptor; B-cell antigen receptor complex-associated protein alpha chain; B-cell antigen receptor complex-associated protein alpha chain-like; B-cell antigen receptor complex-associated protein alpha-chain; Cd79a; CD79A antigen (immunoglobulin-associated alpha); CD79a molecule; CD79a molecule, immunoglobulin-associated alpha; CD79A protein; CD79-alpha protein; EGK |
| Assay Range | 0.65 to 150 ng/mL |
| Assay Sensitivity | 0.65 ng/mL |
| Conjugate | HRP |
| Product Type | ELISA |
| Sample Type | Plasma, Serum, Supernatant |
| For Use With (Equipment) | Colorimetric Microplate Reader |
| Gene ID (Entrez) | 973 |
| Gene Symbol | CD79A |
| Interassay CV | <12% |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?